Filtered By:
Specialty: Cardiology

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 109613 results found since Jan 2013.

Phosphorylation of C/EBP Homologous Protein (CHOP) by the AMP-Activated Protein Kinase Alpha 1 in Macrophages Promotes CHOP Degradation and Reduces Injury-Induced Neointimal Disruption In Vivo.
CONCLUSIONS: Our results indicate that AMPKα1 mediates CHOP ubiquitination and proteasomal degradation in macrophages by promoting the phosphorylation of CHOP at serine 30. We conclude that AMPKα1 might be a valid therapeutic target in preventing atherosclerotic vulnerable plaque formation. PMID: 27650555 [PubMed - as supplied by publisher]
Source: Circulation Research - September 19, 2016 Category: Cardiology Authors: Dai X, Ding Y, Liu Z, Zhang W, Zou MH Tags: Circ Res Source Type: research

Phosphorylation of CHOP (C/EBP Homologous Protein) by the AMP-Activated Protein Kinase Alpha 1 in Macrophages Promotes CHOP Degradation and Reduces Injury-Induced Neointimal Disruption In Vivo.
CONCLUSIONS: Our results indicate that AMPKα1 mediates CHOP ubiquitination and proteasomal degradation in macrophages by promoting the phosphorylation of CHOP at serine 30. We conclude that AMPKα1 might be a valid therapeutic target in preventing atherosclerotic vulnerable plaque formation. PMID: 27650555 [PubMed - in process]
Source: Circulation Research - October 27, 2016 Category: Cardiology Authors: Dai X, Ding Y, Liu Z, Zhang W, Zou MH Tags: Circ Res Source Type: research

Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Pre-Specified Secondary End Points in ORION 1.
Conclusions -Inclisiran produces significant and prolonged reductions in atherogenic lipoproteins, suggesting that inhibiting synthesis of PCSK9 through siRNA may be a viable alternative to other approaches which target PCSK9. Clinical Trial Registration -URL: https://www.clinicaltrials.gov. Unique identifier: NCT02597127. PMID: 29735484 [PubMed - as supplied by publisher]
Source: Circulation - May 7, 2018 Category: Cardiology Authors: Ray KK, Stoekenbroek RM, Kallend D, Leiter LA, Landmesser U, Wright RS, Wijngaard P, Kastelein JJ Tags: Circulation Source Type: research

Delivery of siRNA to Endothelial Cells In Vivo Using Lysine/Histidine Oligopeptide-Modified Poly( β -amino ester) Nanoparticles
ConclusionsWe demonstrate that C6-KH pBAE can used for delivery of siRNAs to the artery endothelium and lung, while minimizing potential side or toxic effects in the liver and heart.
Source: Cardiovascular Engineering and Technology - January 20, 2021 Category: Cardiology Source Type: research

Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease
CONCLUSIONS: SLN360 induces a sustained reduction in serum Lp(a) levels in cynomolgus monkeys following subcutaneous dosing. SLN360 has potential to address the unmet need of Lp(a) reduction in cardiovascular diseases.PMID:35400495 | DOI:10.1016/j.atherosclerosis.2022.03.029
Source: Atherosclerosis - April 11, 2022 Category: Cardiology Authors: David A Rider Mona Eisermann Kathrin L öffler Manuela Aleku Daniel I Swerdlow Sibylle Dames Judith Hauptmann Eliot Morrison Marie Wikstr öm Lindholm Steffen Schubert Giles Campion Source Type: research

Abstract 441: Aldosterone-salt Hypertension Depends on the SFO, Central Aldosterone Synthase and MR Specifically in the PVN Poster Session II
We examined the role of the subfornical organ (SFO), aldo synthesized locally in the brain, and MR specifically in the paraventricular nucleus (PVN) in aldo-salt hypertension. Wistar rats with telemetry probes were treated with chronic intra-cerebroventricular infusion of aldo synthase (AS) inhibitor FAD286 (25 μg/day), MR blocker eplerenone (5 μg/day) or vehicle. After 2 days, subcutaneous (sc) aldo infusion (1 μg/h) was started and saline was provided as drinking water. In a second set of rats with telemetry, electrolytic or sham lesions of the SFO, or bilateral intra-PVN infusion of AAV-MR-siRNA or AAV-SCM-siRN...
Source: Hypertension - October 30, 2013 Category: Cardiology Authors: Huang, B. S., Ahmad, M., Chen, A., White, R. A., Leenen, F. H., Leenen, F. H. Tags: Poster Session II Source Type: research

Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)
AbstractPurpose of ReviewThe aim of low-density lipoprotein-cholesterol (LDL-C) lowering therapies is to safely achieve a consistent and long-term reduction in exposure of the vasculature to atherogenic lipoproteins in order to reduce the risk of atherosclerotic cardiovascular (CV) disease and the associated CV events, such as myocardial infarctions and ischemic strokes. This review summarizes the concept and clinical development of a novel molecular approach to efficiently lower LDL-C, a synthetic small interfering ribonucleic acid (siRNA) —inclisiran—directed against proprotein convertase subtilisin-kexin type 9 (PCS...
Source: Current Cardiology Reports - October 21, 2020 Category: Cardiology Source Type: research

Polyethyieneimine siRNA complexes released from coated electrospun polyethylene terephthalate bypass graft materials facilitate gene silencing in infiltrating primary human aortic smooth muscle cells
Anastomotic intimal hyperplasia (AIH) remains the leading cause of prosthetic arterial graft failure. Use of electrospun PET (ePET) can be an alternative to conventional PET grafts. RNAi is a promising tool to silence genes contributing to AIH, including thrombospondin-2 (TSP-2) previously shown by us to be up-regulated in AIH. Delivery of silencing RNA (siRNA) from ePET graft to the anastomotic sites could potentially mitigate AIH.
Source: Cardiovascular Pathology - May 1, 2013 Category: Cardiology Authors: Christoph S. Nabzdyk, Maggie Chun, Hunter Oliver-Allen, Matthew D. Phaneuf, Saif G. Pathan, Jin-Oh You, Leena Pradhan, Frank W. LoGerfo Tags: Available Online Only: Meeting Abstracts Source Type: research

Calcimimetics increase CaSR expression and reduce mineralization in vascular smooth muscle cells: mechanisms of action
Conclusions The calcimimetic-dependent increase in biosynthesis and activation of the CaSR in h-VSMCs probably play a key role in the protection against calcium-induced VC.
Source: Cardiovascular Research - January 20, 2014 Category: Cardiology Authors: Henaut, L., Boudot, C., Massy, Z. A., Lopez-Fernandez, I., Dupont, S., Mary, A., Drueke, T. B., Kamel, S., Brazier, M., Mentaverri, R. Tags: Vascular biology Source Type: research

Dyslipidaemia: Promising results with siRNA against PCSK9
Nature Reviews Cardiology 14, 252 (2017). doi:10.1038/nrcardio.2017.43 Author: Irene Fernández-Ruiz Two single injections of inclisiran, a small interfering RNA (siRNA) that targets PCSK9 mRNA, induce a 50% reduction in LDL-cholesterol (LDL-C) levels in 6 months, according to findings from the phase II ORION-1 trial presented at ACC.17. A total of 501 patients at high
Source: Nature Reviews Cardiology - March 31, 2017 Category: Cardiology Authors: Irene Fern ández-Ruiz Tags: Research Highlight Source Type: research

Transcriptional regulation of stress kinase JNK2 in pro-arrhythmic CaMKII δ expression in the aged atrium
ConclusionJNK2 activation up-regulates CaMKII δ expression in the aged atrium. This JNK2 regulation in CaMKIIδ expression occurs at the transcription level through the JNK downstream transcription factor c-jun. The discovery of this novel molecular mechanism of JNK2-regulated CaMKII expression sheds new light on possible anti-arrhythmia drug development.
Source: Cardiovascular Research - January 19, 2018 Category: Cardiology Source Type: research

Novel siRNA reduces plasma lipoprotein(a) levels
Nature Reviews Cardiology, Published online: 25 January 2022; doi:10.1038/s41569-022-00673-1Novel siRNA reduces plasma lipoprotein(a) levels
Source: Nature Reviews Cardiology - January 25, 2022 Category: Cardiology Authors: Gregory B. Lim Source Type: research

The Potential Impact of Statins in the Treatment of Patients with COVID-19 Infection
CONCLUSION: Patients with SARS-CoV-2 infection have a high risk of cardiovascular and thrombotic complications and pleiotropic effects of statins may help manage the COVID-19. There is growing evidence that supports the need for trials of statin treatment in COVID-19 infection.PMID:35132599 | DOI:10.1007/978-3-030-85109-5_9
Source: Atherosclerosis - February 8, 2022 Category: Cardiology Authors: Reza Jafarzadeh Esfehani Mohammad Vojdanparast Saman Soleimanpour Gordon A Ferns Amir Avan Source Type: research

Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease
The LPA gene encodes apolipoprotein (a), a key component of Lp(a), a potent risk factor for cardiovascular disease with no specific pharmacotherapy. Here we describe the pharmacological data for SLN360, a GalNAc-conjugated siRNA targeting LPA, designed to address this unmet medical need.
Source: Atherosclerosis - April 1, 2022 Category: Cardiology Authors: David A. Rider, Mona Eisermann, Kathrin L öffler, Manuela Aleku, Daniel I. Swerdlow, Sibylle Dames, Judith Hauptmann, Eliot Morrison, Marie Wikström Lindholm, Steffen Schubert, Giles Campion Source Type: research